Aethlon Medical Q2 Net Loss Narrows to $1.55M; Raises $4.0M

Aethlon Medical reported a reduced net loss of $1.55 million for the three months ended June 30, 2026, compared to $1.76 million in the prior year, with operating expenses decreasing by 11.9%. The company strengthened its liquidity by raising $1.82 million net through an at-the-market offering during the quarter and an additional $4.0 million gross in a public offering subsequent to quarter-end. A 1-for-5 reverse stock split was effected in July 2026, and the Australian oncology clinical trial for Hemopurifier is ongoing. Management believes current capital is sufficient for at least 12 months of planned operations.